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This knowledge-based activity is targeted for all pharmacists 
and is acceptable for 1.0 hour (0.1 CEU) of continuing 
education credit. This course requires completion 
of the program evaluation and at least a 70 percent grade 
on the program assessment questions. 
ACPE Universal Activity Number (UAN): 0048-0000-14-032-HO 1-P 
Objectives 
After completion of this program, the reader should be able 
to: 
1. Explain the etiology, patient presentation and 
diagnosis of Celiac disease. 
2. Discuss the current therapy for Celiac disease, 
highlighting the gluten-free diet. 
3. Identify investigational pharmacotherapeutic options 
for Celiac disease. 
4. Define the pharmacist's role in patient education 
and counseling for Celiac disease. 
Abstract 
Celiac disease is a genetically-linked autoimmune disease 
which affects the gastrointestinal tract. It is an inflammatory 
reaction to ingested gluten-containing substances that pro-
duces the most frequent symptoms of abdominal pain, bloat-
ing and intermittent or chronic diarrhea. Diagnosis can be 
made by blood testing for specific IgA autoantibodies and a 
confirmation duodenal biopsy to look for the characteristic 
scalloping and villous atrophy that occurs in response to the 
inflammation. A gluten-free diet, until recently, was the only 
treatment available and continues to be the mainstay of 
treatment Newer adjunct therapies to dietary management 
include larazotide acetate, peptidases, the use of parasite 
Necator americanus, a desensitizing vaccine, polymeric bind-
ers, cytokine antagonists, tissue transglutaminase inhibitors, 
probiotics and anti-inflammatory therapy. This review will 
outline the potential of each of these therapies and discuss 
the role of the pharmacist in assisting patients with Celiac 
disease. 
Introduction 
In recent years, Celiac disease has emerged in society as a 
common, genetically-linked condition affecting the gastroin-
testinal (GI) system. It is an autoimmune disease that leads to 
gastrointestinal side effects as a result of ingestion of gluten-
containing substances. The disease has risen in prevalence as 
physician awareness and diagnosis of the condition has in-
creased. Still, many patients live with the condition and deal 
with the symptoms while remaining undiagnosed. Celiac 
disease can negatively affect patient quality of life for a 
multitude of reasons. These include physical discomfort as-
sociated with the disease as well as the inconvenience of 
maintaining a gluten-free diet, which is currently the only 
treatment option. 
Several new pharmacological therapies and drug targets are 
under investigation for relief of symptoms and may be viable 
options for use as adjunct therapy in Celiac disease patients. 
While none of these products are currently on the market, 
they have the potential to be realistic additions to therapeu-
tic regimens in the future. Pharmacists have an important 
role in counseling patients about the disease and how to 
manage symptoms. They will be sought out as drug experts 
for the disease state, as well as excellent resources for infor-
mation about gluten-free foods and medications. The number 
of patients with Celiac disease will only continue to increase, 
and it is important to be knowledgeable about the disease 
state and incorporate patient counseling and education into 
pharmacists' everyday practice. 
Disease Overview 
Celiac disease is an increasingly prominent disease state that 
is highly linked to genetic factors. Such genetic factors are 
linked to mutations on the human leukocyte antigen (HLA) 
Class II genes, specifically haplotypes HLA-DQ2 and HLA-
DQ8, found on the 6p21 chromosome.1 Genetic mutations are 
the most predominant factor in eliciting the immune-
mediated response to gluten, as 4 to 12 percent of Celiac dis-
ease patients have a first degree relative also suffering from 
this disease state.2 It is important to note, however, that 30 to 
40 percent of Caucasians have these HLA mutations with 
only 2 to 5 percent of carriers presenting with Celiac disease 
signifying that genetic mutations are necessary for disease 
presentation but are not the sole cause of Celiac disease.1 
While genetic predisposition is important to consider, other 
factors may also contribute to the development of Celiac dis-
ease. These include environmental factors, such as a past 
enteric infection or patients who are exposed to gluten prior 
to 4 months of age.1 Furthermore, patients who suffer from 
other immune-mediated genetic disorders that affect the GI 
tract, such as Crohn's disease and ulcerative colitis, are more 
susceptible than other individuals to develop this disease state.2 
Celiac disease is classified as an immune-mediated disorder, 
as its symptomatic presentation is due to gluten, which trig-
gers immunological reactions.3 These immunological reac-
tions stimulate an autoimmune response by the cells of the 
GI tract, stimulating inflammatory mediators.4 Inflammatory 
mediators present in Celiac disease may lead to the opening 
of tight junctions in the intestinal epithelium. Tight junctions 
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regulate fluid and molecule passage between intestinal 
epithelial cells to the lamina propria. Proteins known as 
zonula occludins also regulate the structure and function of 
the cellular cytoskeleton by linking tight junctions with the 
actin network. When the tight junctions are not functioning 
properly, gluten (or gliaden) peptides gain access across the 
intestinal epithelium and are then modified by the enzyme, 
tissue transglutaminase (tTG).1· s T-cells will then present the 
modified gluten as an antigen via HLA-DQZ and HLA-DQB 
proteins. Gluten presentation then initiates both humoral 
and cell-mediated immune responses, leading to a temporary 
and reversible remodeling of intestinal mucosa, including 
scalloping of the small intestine mucosa and villous atrophy 
leading to malabsorption and symptoms such as abdominal 
pain, bloating and diarrhea.1 
Patient Presentation 
Celiac disease is prevalent across ethnicities, ages and gen-
ders with increasing prevalence not only in the pediatric 
population but also the adult population. Symptoms present 
in 1 percent of the U.S. population but may be undiagnosed in 
up to 85 to 90 percent of cases.1.2 Celiac disease classically 
presents with symptoms related to malabsorption of gluten, 
which can include but are not limited to abdominal pain, 
bloating and intermittent or chronic diarrhea.1.3 Chronic di-
arrhea is due to changes in the gastrointestinal wall leading 
to malabsorption of gluten, and can cause dehydration, 
weight loss and muscle wasting. Further signs of Celiac dis-
ease include anemia, most commonly iron-deficiency, due to 
malabsorption. Vitamin D deficiency and Vitamin 812 defi-
ciency can also be signs of Celiac disease.1 Of those patients 
with Celiac disease, 15 to 25 percent present with the non-
traditional symptom of dermatitis herpetiformis, a rash that 
occurs without the accompaniment of GI symptoms.2 The 
inflammatory process associated with dermatitis herpeti-
formis results from lgA deposition and neutrophil accumula-
tion, which leads to vesicle formation, producing a rash com-
monly found on the elbows, knees and buttocks, an impor-
tant clinical observation for patients with suspected Celiac 
disease.2 
Due to similar GI symptoms across various GI disorders, it is 
important to note that some patients who suffer from Celiac 
disease also have a secondary disorder including lactose in-
tolerance or inflammatory bowel disease (IBD). 1 Those pa-
tients suffering from autoimmune diseases including type 1 
diabetes mellitus and autoimmune thyroid disorder may be 
more likely to present with Celiac disease and should be 
tested regardless of symptom presentation.1,3 Celiac disease 
patients may also be more likely to have other immune-
mediated diseases that affect the GI tract, such as Crohn's 
disease or ulcerative colitis.2 Patients who have been diag-
nosed with lactose intolerance or diarrhea-predominant IBD 
and have not showed improvement should consider being 
tested for Celiac disease. The diagnosis process is an impor-
tant step for patients because, although death is not a com-
mon outcome of this disease state, patients with multiple 
disease states are at an increased risk for complications such 
as vitamin deficiencies, malnutrition, ulcerative jejunitis, 
T-cell lymphoma and an overall decrease in quality oflife.1 
Diagnosis 
Diagnosis is vital for patients suffering from Celiac disease 
due to a fourfold increase in mortality in patients with an 
untreated disease state.7 Patients who present with Celiac 
disease symptoms should be screened via a blood test or in-
testinal biopsy.2 Furthermore, asymptomatic patients who 
have a first-degree or second-degree relative with confirmed 
Celiac disease, type 1 diabetes, autoimmune thyroid disor-
ders, rheumatoid arthritis or GI associated autoimmune dis-
order should be tested for Celiac disease. The first step for 
suspected patients is testing a blood sample for specific IgA 
autoantibodies via immunofluorescence. For patients under-
going a blood sample, it is important to eat foods containing 
gluten prior to testing, otherwise the patient may receive a 
false negative result for Celiac disease.1 Those patients suf-
fering from Celiac disease will present with elevated IgA to 
tTG or epithelial membrane antigen (EMA).2 Most likely, tTG 
IgA will be screened due to its cost efficiency and comparable 
accuracy to the EMA IgA test. Another method of testing is 
via an upper endoscopy with duodenal biopsies to look for 
scalloping of the folds or cracking of the small intestine as 
well as villous atrophy linked to inflammatory changes. Due 
to the biopsy expense, this step in diagnosis should be sug-
gested after blood testing in order to confirm the disease 
state.1 
Treatment 
Treatment should be started once Celiac disease is suspected. 
Currently, a gluten-free diet is the only therapeutic option for 
patients with Celiac disease. Gluten can be found in wheat, 
barley and rye containing products. Due to cross-
contamination in manufacturing, it is very difficult to com-
pletely avoid the irritating substances. Due to the difficulty 
finding specifically gluten-free foods, many Celiac disease 
patients are exposed to low levels of gluten on a regular ba-
sis. Also, many medications have inert ingredients that con-
tain gluten, making total avoidance even more difficult. It is 
estimated that 30 to 50 percent of patients are not able to 
strictly adhere to the proper diet, and at any given time 50 
percent of all Celiac disease patients have an active disease 
state.4 A gluten-free diet will aid in the healing of intestinal 
mucosa.1 Those patients who suffer from dermatitis herpeti-
formis can treat the rash with dapsone, which inhibits 
neutrophil recruitment and downstream inflammatory proc-
esses, if the rash does not resolve after committing to a glu-
ten-free diet,1.6 About 90 percent of patients will present 
with no symptoms after five years of a gluten-free diet, and 
almost all patients will experience some relief from symp-
toms immediately after beginning the diets Those patients 
who follow a strict gluten-free diet have a better, long-term 
quality of life due to greater and more consistent relief, as 
well as an overall enhanced state of health (i.e. mental health, 
pain, vitality, social function, physical function).9 Overall, re-
lief of Celiac disease symptoms is due to a decrease in lgA 
specific autoantibody production via removal of the antigen 
(gluten).10 Patients continuing to suffer from symptoms can 
more rigorously utilize pharmacological agents to treat 
symptoms related to deficiencies in Vitamin 812, Vitamin D 
and folic acid. Furthermore, nonsteroidal anti-inflammatory 
agents (NSAIDs) and anti-diarrheals can be used for symp-
Gastroenterology Celiac Disease: Current and lnvestigational Therapies and the Role of the Pharmacist 
tom management. If symptoms persist after symptom man-
agement and strict adherence to a gluten-free diet, it is rec-
ommended that the patient revisit his or her doctor to deter-
mine if the patient is suffering from an additional disorder. 11 
New Pharmacological Therapies 
New pharmacological therapies are in development to treat 
Celiac disease as an adjunct to the gluten-free diet. These 
novel therapies are necessary to increase the quality of life in 
patients who are still exposed to gluten even with best ef-
forts to avoid the offending agent.4 Currently, many different 
methods of therapy have been investigated, including larazo-
tide acetate, peptidases, the use of parasite Necator ameri-
canus, a desensitizing vaccine, polymeric binders, cytokine 
antagonists, tissue transglutaminase inhibitors, probiotics 
and anti-inflammatory therapy.4.12,13 
Cellular exposure to gluten can be reduced by use of larazo-
tide acetate, a therapy in development. Larazotide acetate 
(ALBA Therapeutics) acts on the cytoskeleton to prevent 
opening of tight junctions and reduce gluten transport into 
cells from the intestinal lumen.4 It also promotes redistribu-
tion and reorganization of zonula occludins and other pro-
teins that associate with actin in the cytoskeleton. ALBA 
Therapeutics conducted a study testing the effects of larazo-
tide acetate on junction assembly in kidney and intestinal 
cells. This study was conducted in vitro and showed promis-
ing results through several mechanisms including promotion 
of tight junction assembly, actin reorganization for stronger 
assembly of tight junctions, GTPase regulation of the cy-
toskeleton and inhibition of tight junction disassembly. 5 Im-
proved tight junctions will lessen intestinal cell exposure to 
gluten, which can reduce inflammatory reactions in the GI 
tract. 
Furthermore, in a randomized, placebo-controlled study by 
Kelly et al., the efficacy of larazotide acetate was assessed in 
patients receiving small amounts of gluten daily (2.7 g of glu-
ten, equivalent to one slice ofbread) .14 The primary endpoint 
of the study was a measure of intestinal permeability known 
as the lactulose-to-mannitol (LAMA) ratio. Patients with Ce-
liac disease have an increased LAMA ratio. Results showed 
no statistical differences in LAMA ratio between placebo and 
treatment groups; however, the study acknowledged flaws in 
timing of LAMA assay and outpatient testing that may have 
affected results. Secondary endpoints included measures of 
serum anti-tTG IgA levels and showed the greatest increase 
in the placebo group from zero to six weeks, in which 30 per-
cent of patients in the group seroconverted. Serum concen-
trations of the treatment group remained below levels that 
qualify a positive antibody test.14 When compared to placebo, 
the treatment groups showed significantly lower anti-tTG 
IgA levels (1 mg dose p=0.010, 4 mg dose p=0.005, 8 mg dose 
p=0.025). There was also evidence to suggest that patients 
treated with larazotide acetate had fewer gastrointestinal 
side effects when compared to placebo. However, only the 
1 mg daily dose of larazotide acetate reached statistically 
significant lower scores in patient-reported abdominal pain, 
indigestion and diarrhea versus placebo by the end of the 
treatment period (p=0.017).14 
Another randomized, double-blinded, placebo-controlled 
study by Leffler et al. also had a primary endpoint of changes 
in LAMA ratio as well as measures of serum tTG antibodies. 
Results were similar to the Kelly et al. study, with the 
changes in LAMA ratio not reaching statistical significance. 
However, serum tTG did not reach statistically lower levels 
in this study. This study did show a significant difference in 
severity of gastrointestinal side effects between the patients 
receiving larazotide acetate with a gluten challenge versus 
the gluten challenge control group as evidenced by the Gas-
trointestinal Symptom Rating Scale (p<0.05).15 Results from 
all three studies suggest that larazotide acetate has the bene-
fit of inhibiting the opening of tight junctions in intestinal 
cells. Larazotide acetate may in the future have the possible 
therapeutic use as an adjunct to a gluten-free diet and relief 
of some symptoms of Celiac disease.5.11,15 
Another novel drug therapy for the treatment of Celiac dis-
ease is the use of oral peptidases to hydrolyze gluten poly-
peptides. In this form, the gluten molecules can no longer 
stimulate damaging intestinal immune responses. Alvine 
Pharmaceuticals has developed ALV003, a combination of 
two gluten-sensitive peptidases. The company DSM has also 
developed a peptidase (AN-PEP), and a third is being tested 
by Stanford University. A phase I clinical trial showed that 
the use of ALV003 for pretreatment of gluten ingestion in 
Celiac disease patients caused a decrease in activation of im-
munological markers, as well as benefit in breaking down 
high gluten-containing foods.4 However, this trial was under-
powered and did not achieve statistically significant values 
for serology or symptom improvement. AN-PEP has showed 
less success in reaching significant endpoints in trials. How-
ever, AN-PEP is being considered as a food supplement as it 
is particularly active at degrading gluten in the stomach. One 
drawback of peptidase use is the susceptibility of these pep-
tides to the acidic conditions of the stomach, and modifica-
tion with polymer substitutes has been considered.12 Use of 
oral peptidases has been one of the most investigated thera-
peutic options for the treatment of Celiac disease; however, 
its role in clinical practice has yet to be determined. 
The use of the parasite N ecator americanus is another inves-
tigational therapy for Celiac disease patients. Trials are un-
derway to test whether or not this helminth infection can 
attenuate the autoimmune intestinal inflammation associ-
ated with Celiac disease.16 The theory behind this therapy is 
derived from the hygiene hypothesis: the notion that increas-
ing numbers of allergic and autoimmune disorders in devel-
oped countries may be associated with the decrease of infec-
tious diseases present in society.16,17 In a prospective, pla-
cebo-controlled, randomized, double-blind trial by Daveson 
et al., Necator americanus infection in Celiac disease patients 
was evaluated with primary endpoints of duodenal histology 
scores (for intestinal damage) and systemic interferon-
gamma levels (for inflammation). Inoculation with the worm 
was instituted in patients who subsequently underwent a 
gluten challenge. A placebo group underwent the same glu-
ten challenge without the worm for comparison. Results 
showed no statistical difference in duodenal histology scores 
or interferon-gamma levels between the infected and control 
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groups. This study in particular shows that helminth infec-
tion may not alleviate the need for a gluten-free diet in Celiac 
disease.16 Limited studies using this therapy have been inves-
tigated at this time, and currently helminth infection therapy 
is not seen as a therapeutic option used in clinical practice. 
Desensitization through the use of a Celiac disease-specific 
vaccination is also an investigational therapy. The biotech-
nology company ImmuSanT has developed a vaccine, Nex-
vax2®, which contains immunogenic gluten peptides from 
wheat, barley and rye. The vaccine was developed with the 
goal of restoring gluten-tolerance in Celiac disease patients 
through use as an immunotherapeutic and prophylactic 
agent,12 A phase I study has evaluated the safety and efficacy 
of weekly intradermal injections of Nexvax2® compared to 
placebo by measuring immune T-cell response. The study's 
formally written publication has not yet been released. 
Thirty-four HLA-DQ2+ Celiac disease patients were random-
ized to four treatment groups (receiving 9 mcg, 30 mcg, 60 
mcg and 90 mcg of Nexvax2® weekly for three weeks) and a 
placebo group (receiving saline injections on the same sched-
ule). Results showed that the incidence of GI side effects was 
similar in the treatment and placebo groups. In the treatment 
group, immunological responses to Nexvax2® were similar to 
acute exposure to oral gluten (gluten ingestion) in the mobi-
lization of gluten-specific T-cells,IB.19 Patients receiving the 
vaccine were found to have interferon-gamma-producing 
Nexvax2®-specific T-cells, which validates the bioactivity of 
the vaccine through immunological response. The hope is 
that through repeated vaccinations, a Celiac disease patient 
will develop tolerance to the immunogenic gluten peptides 
and be able to incorporate small amounts of gluten into his 
or her diet.12 Thus far, data are extremely limited on the effi-
cacy of such a therapy and more trials are needed. This may 
be a viable option in the future and an additional agent that 
could improve the quality of life of Celiac disease patients. 
Many new therapeutic options for the treatment of Celiac 
disease are in very early stages of development. It may be 
some time before viable options are commercially available 
or before they become standards of practice for treatment. 
However, the amount of research and development into 
pharmacological therapies for Celiac disease is promising, 
and awareness and knowledge of these therapies are critical 
for pharmacists to be prepared for potential changes in Ce-
liac disease state management in the future. 
Pharmacists' Role 
Pharmacists have a key role in improving the quality of life 
for patients suffering from Celiac disease and thus are best 
able to share important medication-nutrition and nutrition-
disease state interactions with patients.20 Resources for pa-
Table 1. Drug Excipients That are Safe or Require Further Investigation in Celiac Disease Patients21.22 
Gluten-free Ingredients 
Benzyl alcohol 
Cellulose 
Cornstarch 
Croscarmellose sodium 
Fructose 
Gelatin 
Glycerin 
Lactose 
Mannitol 
Polysorbates 
Silicon dioxide 
Sodium lauryl sulfate 
Stearates 
Sucrose 
Titanium dioxide 
Ingredients Needing Further Investigation (if source not specified) 
Caramel coloring 
Dextrate 
Dextrimaltose 
Dextrin 
Maltodextrin 
Modified starch 
Potato 
Pregelatinized modified starch 
Pregelatinized starch 
Sodium starch glycolate 
Starch 
Tapioca 
Note: This chart is not an exhaustive list of gluten-free or gluten-containing ingredients used in medications. If there is ever 
a question about a specific medication ingredient, the drug manufacturer should be contacted for inquiry. 
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tient advising can be found through the National Foundation 
for Celiac Awareness (NFCA) at www.celiaccentral.org. Pa-
tient resources and brochures include information regarding 
what is Celiac disease, the choice to be gluten free, Celiac dis-
ease and women's health, and a Celiac disease symptoms 
checklist.21 This information is free and available for pharma-
cists to provide to patients and will afford patients a better 
understanding of the disease. 
Another important concern for pharmacists is the identifica-
tion of gluten in various medications and over-the-counter 
products including vitamins, supplements and lip balms. 
These less obvious sources of gluten have been found to ex-
acerbate patients' symptoms and should be monitored.1 It is 
important for pharmacists to be aware of the excipients pre-
sent in medications, especially because generic medications 
are not required to use the same excipients as the brand 
name medication. Likewise, not all generics are equal, and 
even two generics for the same medication may not contain 
the same excipients. Table 1 provides a list of excipients that 
are gluten-free and those ingredients that may need further 
investigation (if source not specified) to ensure safety. A 
drug manufacturer should be contacted if the pharmacist or 
patient is unsure of the excipient used, the source of the ex-
cipient or the possibility of cross contamination. As medica-
tion experts, pharmacists should know how to obtain this 
information for an inquiring patient.22 Pharmacists and pa-
tients can find extensive lists of brand and generic prescrip-
tion medications as well as over-the-counter medications 
that do not contain gluten at glutenfreedrugs.com. This web-
site is kept up to date by a clinical pharmacist who continu-
ally updates the information for public access.23 
Pharmacists are also an accessible resource for patients to 
approach about gluten-free food options and healthy living 
while on this restricted diet. It is important for pharmacists 
to counsel on the extra cost associated with preparing 
gluten-free foods and for patients to consider this in their 
budget. Equally important is directing patients to the afore-
mentioned resources about Celiac disease for additional as-
sistance. In order to help those patients on a gluten-free diet, 
labeling requirements have been added that mandate food 
labels to identify wheat and other common food allergens, as 
a result of a rising prevalence of patients suffering from Ce-
liac disease and gluten intolerance. Additional requirements 
include regulations by the U.S. Food and Drug Administration 
(FDA) to control rules for the use of the term "gluten-free" on 
products. The FDA has standardized their definition of 
"gluten-free" such that foods containing this term or claiming 
to contain "no gluten," "free of gluten" and "without gluten" 
must contain less than 20 parts per million of gluten, an 
amount not seen to harm patients with Celiac disease. 24 
Conclusion 
Celiac disease is gammg more and more recognition by 
health care professionals as the prevalence of the disease 
state increases. It is a genetically-linked disease whose diag-
nosis and treatment can lead to improved patient quality of 
life. While current practice only champions the gluten-free 
diet for treatment, newer investigational pharmacotherapy 
may emerge in the near future. Pharmacists will remain an 
important resource for patient education about Celiac dis-
ease. Pharmacists will be called upon to investigate medica-
tions and foods that may be appropriate or inappropriate in 
Celiac disease. Patient care is always a number one goal, and 
knowledge of this condition will allow pharmacists to be a 
primary resource for the treatment of Celiac disease. 
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DocumentsRegulatorylnformation/ Allergens/ucm362880.htm. 
Gastroenterology 
Gastroen terology Celiac Disease: Current and lnvestigational Therapies and the Role of the Pharmacist 
Assessment Questions 
Etiology 
l. Development of Celiac disease is genetically linked to 
which two haplotypes found on the mutated HLA Class II 
gene? 
A. 
B. 
c. 
D. 
HLA-DQ2 
HLA-DQB 
HLA-DQ21 
Both A and B 
E. Both A and C 
Patient Presentation 
2. Symptoms of Celiac disease include all of the following 
EXCEPT: 
A. Abdominal pain 
B. Bloating 
C. Cyanosis 
D. Diarrhea 
E. Iron deficiency 
Diagnosis 
3. What counseling should be provided to a patient who is 
having a blood test for Celiac disease diagnosis? 
A. Eat gluten prior to the blood test 
B. Do not eat gluten prior to the blood test 
C. Fast for 12 hours prior to the blood test 
D. Exercise one hour prior to the blood test 
E. None of the above 
Treatment 
4. Relief of symptoms in Celiac disease patients is rooted in 
a decrease in which autoantibody? 
A. IgA 
B. IgD 
C. lgE 
D. IgG 
E. All of the above 
5. After five years of following a gluten-free diet, about 
__ of Celiac disease patients will be completely 
symptom free. 
A. 1% 
B. 10% 
c. 25% 
D. 50% 
E. 90% 
6. Which of the following is NOT true about following a 
strict gluten-free diet? 
A. Following a gluten-free diet will improve patient 
quality of life. 
B. Patients who follow a gluten-free diet and no 
longer have symptoms do not need to visit their 
doctor for reevaluation. 
C. Patients who follow a gluten-free diet have a 
better health status. 
D. Patients who follow a gluten-free diet have a 
greater and more consistent relief of symptoms. 
lnvestigational Therapy 
7. Larazotide acetate is a novel therapeutic option for 
Celiac disease whose mechanism of action includes: 
A. Manipulation of the cytoskeleton to facilitate 
tight junction opening 
B. Actin reorganization for better assembly 
C. Inhibition of tight junction disassembly 
D. Both A and B 
E. Both B and C 
8. Therapeutic use of gluten peptidases show the 
advantage of: 
A. Decrease in activation of immunologic markers 
B. Use as monotherapy for treatment of Celiac 
disease 
C. Gluten peptides are unsusceptible to acidic 
conditions in the stomach 
D. All of the above 
9. The desensitization vaccine, Nexvax2®: 
A. ls currently on the market and available for 
patient use 
B. Targets three gluten peptides found in wheat, 
barley and rye 
C. Has an increased incidence of GI side effects 
compared to ingestion of gluten 
D. Recently completed phase III clinical trials 
Pharmacists' Role 
10. If a patient has a question about gluten in medications, a 
pharmacist should: 
A. Tell the patient to check the medication 
ingredients on their own. 
B. Explain that all medications are gluten-free and 
they should not worry. 
C. Contact the drug manufacturer about 
questionable ingredients or with concerns 
about cross-contamination. 
D. Assure patients that a small amount of gluten 
will not effect their condition. 
~. Ohio Northern University is accredited by the Accreditation Council for Phannacy Education as a provider of continuing pharmacy education. This program is eligible for credit until 02/25/2017. 
To receive continuing education credit for this program, you 
must answer the above questions and fill out the evaluation 
form. Please visit www.onu.edu/pharmacy to enter the 
required information. Please allow two to three weeks for 
electronic distribution of your continuing education certifi-
cate, which will be sent to your valid email address in PDF 
format. 
To receive continuing education credit for this program, visit www.onu.edu/pharmacy/CE OR fill out the form below 
including your indicated answers to the assessment questions and return to: 
Office of Continuing Education at the Raabe College of Pharmacy 
Ohio Northern University 
525 South Main Street 
Ada, Ohio 45810 
Program Title: Celiac Disease: Current and Investigational Therapies and the Role of the Pharmacist 
UAN: 0048-0000-14-032-HOl-P CEUs: 0.1 
All information must be printed CLEARLY to ensure accurate record keeping for attendance and the awarding of 
continuing education credit. Certificates will be distributed as a PDF document to a valid email address. 
Name: 
Address: 
City: State: Zip: 
Phone: Email: 
Pharmacy License #: State: ONU Alumni? y N 
The program objectives were clear. 1 2 3 4 5 
The program met the stated goals and objectives: 
Explain the etiology, patient presentation and diagnosis 1 2 3 4 5 
of Celiac disease. 
Discuss the current therapy for Celiac disease, high- 1 2 3 4 5 lighting the gluten-free diet. 
Identify investigational pharmacotherapeutic options 1 2 3 4 5 for Celiac disease. 
Define the pharmacist's role in patient education and 1 2 3 4 5 
counseling for Celiac disease. 
The program met your educational needs. 1 2 3 4 5 
Content of the program was interesting. 1 2 3 4 5 
Material presented was relevant to my practice. 1 2 3 4 5 
Comments/Suggestions for future programs: 
Thank you! 
Answers to Assessment Questions-Please Circle Your Answer 
1. ABCDE 4. A B C D E 
2. A B C D E 5. A B C D E 
3. A B C D E 6. A B C D 
Any questions/comments regarding this continuing education program can 
be directed to Lauren Hamman, Advanced Administrative Assistant for the 
Office of Continuing Education (email: l-hamman@onu.edu, phone 419-
772-2280). 
7. A B C D E 10. A B C D 
8. A B C D 
9. A B C D 
~1 Ohio Northern University is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is eligible for credit until 02/25/2017. 
